Interaction between Single Nucleotide Polymorphisms in Selenoprotein P and Mitochondrial Superoxide Dismutase Determines Prostate Cancer Risk

被引:90
作者
Cooper, Matthew L.
Adami, Hans-Olov [2 ,3 ,4 ]
Gronberg, Henrik [2 ]
Wiklund, Fredrik [2 ]
Green, Fiona R.
Rayman, Margaret P. [1 ]
机构
[1] Univ Surrey, Div Nutr Sci, Fac Med & Hlth Sci, Guildford GU2 7XH, Surrey, England
[2] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[4] Dana Farber Harvard Canc Ctr, Boston, MA USA
关键词
D O I
10.1158/0008-5472.CAN-08-1827
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Selenium may affect prostate cancer risk via its plasma carrier selenoprotein P which shows dramatically reduced expression in prostate cancer tumors and cell lines. The selenoprotein P (SEPP1) Ala234 single nucleotide polymorphism (SNP) allele is associated with lower plasma selenoprotein P in men, reducing the concentration/activity of other antioxidant selenoproteins. Selenium status also modifies the effect of the mitochondrial superoxide dismutase (SOD2) SNP Ala16Val on prostate cancer risk. We investigated the relationship of these SNPs with prostate cancer risk. DNA from 2,975 cases and 1,896 age-matched controls from the population-based Prostate Cancer in Sweden study were genotyped using TaqMan assays. Cases were designated aggressive or nonaggressive prostate cancers at diagnosis by clinical criteria. Association with prostate cancer was investigated by logistic regression; gene-gene interaction using a general linear model. The mean plasma selenium concentration measured in 169 controls was relatively low (76.0 +/- 17.2 mu g/L). SNP genotype distributions were in Hardy-Weinberg equilibrium. SOD2-Ala16+ men were at a greater risk of prostate cancer [odds ratios (OR), 1.19; 95% confidence intervals (CI), 1.03-1.37] compared with SOD2-Va16 homozygotes. Men homozygous for SEPP1-Ala234 who were also SOD2-Ala16+ had a higher risk of prostate cancer (OR, 1.43; 95% CI, 1.17-1.76) and aggressive prostate cancer (OR, 1.60; 95% CI, 1.22-2.09) than those who were SOD2-Val16 homozygotes (interaction, prostate cancer P = 0.05; aggressive prostate cancer P = 0.01). This interaction was stronger in ever-smokers: SOD2-Ala16+ men homozygous for SEPP1-Ala234 had an almost doubled risk of prostate cancer (OR, 1.97; 95% CI, 1.33-2.91; interaction P = 0.001). In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H2O2 that they cannot remove, thereby promoting prostate tumor cell proliferation and migration. (Cancer Res 2008;68(24):10171-7]
引用
收藏
页码:10171 / 10177
页数:7
相关论文
共 42 条
[1]   Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP in colorectal carcinogenesis [J].
Al-Taie, OH ;
Uceyler, N ;
Eubner, U ;
Jakob, F ;
Mörk, H ;
Scheurlen, M ;
Brigelius-Flohe, R ;
Schöttker, K ;
Abel, J ;
Thalheimer, A ;
Katzenberger, T ;
Illert, B ;
Melcher, R ;
Köhrle, J .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2004, 48 (01) :6-14
[2]   Selenium status and its correlates in a British National Diet and Nutrition Survey: people aged 65 years and over [J].
Bates, CJ ;
Thane, CW ;
Prentice, A ;
Delves, HT .
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2002, 16 (01) :1-8
[3]  
Calvo A, 2002, CANCER RES, V62, P5325
[4]   HYDROPEROXIDE METABOLISM IN MAMMALIAN ORGANS [J].
CHANCE, B ;
SIES, H ;
BOVERIS, A .
PHYSIOLOGICAL REVIEWS, 1979, 59 (03) :527-605
[5]   Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial - A randomized controlled trial [J].
Clark, LC ;
Combs, GF ;
Turnbull, BW ;
Slate, EH ;
Chalker, DK ;
Chow, J ;
Davis, LS ;
Glover, RA ;
Graham, GF ;
Gross, EG ;
Krongrad, A ;
Lesher, JL ;
Park, HK ;
Sanders, BB ;
Smith, CL ;
Taylor, JR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (24) :1957-1963
[6]   Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model [J].
Diwadkar-Navsariwala, Veda ;
Prins, Gail S. ;
Swanson, Steven M. ;
Birch, Lynn A. ;
Ray, Vera H. ;
Hedayat, Samad ;
Lantvit, Daniel L. ;
Diamond, Alan M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (21) :8179-8184
[7]  
Duffield AJ, 1999, AM J CLIN NUTR, V70, P896
[8]  
Duffield-Lillico AJ, 2002, CANCER EPIDEM BIOMAR, V11, P630
[9]   Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial [J].
Duffield-Lillico, AJ ;
Dalkin, BL ;
Reid, ME ;
Turnbull, BW ;
Slate, EH ;
Jacobs, ET ;
Marshall, JR ;
Clark, LC .
BJU INTERNATIONAL, 2003, 91 (07) :608-612
[10]   Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB21P [J].
Duggan, David ;
Zheng, Siqun L. ;
Knowlton, Michele ;
Benitez, Debbie ;
Dimitrov, Latchezar ;
Wiklund, Fredrik ;
Robbins, Christiane ;
Isaacs, Sarah D. ;
Cheng, Yu ;
Li, Ge ;
Sun, Jielin ;
Chang, Bao-Li ;
Marovich, Leslie ;
Wiley, Kathleen E. ;
Balter, Katarina ;
Stattin, Par ;
Adami, Hans-Olov ;
Gielzak, Marta ;
Yan, Guifang ;
Sauvageot, Jurga ;
Liu, Wennuan ;
Kim, Jin Woo ;
Bleecker, Eugene R. ;
Meyers, Deborah A. ;
Trock, Bruce J. ;
Partin, Alan W. ;
Walsh, Patrick C. ;
Isaacs, William B. ;
Gronberg, Henrik ;
Xu, Jianfeng ;
Carpten, John D. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (24) :1836-1844